The lack of a big response shows how many holders are just trading VIVUS and have no idea of the value of today's news. Waiting to see if the traders even sell out positions going into the weekend and give better entries.
The scope of the news will be validated by Wall Street analysts (after) they collect shares and have a sizable position that will benefit from a double in the market price. End of next week may see those analyst upgrading.
If no one else noticed the PR states that "... for over a year showed improved blood pressure, cholesterol and triglyceride levels," As far as I know there has been no "study" lasting over a year that has concluded recently. The PR today and posting online in whatever journal (American Journal of Cardiology I think) is a rehash of the information that was presented to the FDA a year or more ago during the approval process.
Just another example of Leland working the crowds ........ I'll bet he's PO'd that the pps didn't go higher and hold so that he and the boys could exercise a few options. Don't think it went high enough but keep your eyes on the SEC filings the next few days.